• Je něco špatně v tomto záznamu ?

Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy

AK. Wani, R. Singh, N. Akhtar, A. Prakash, E. Nepovimova, P. Oleksak, Z. Chrienova, S. Alomar, C. Chopra, K. Kuca

. 2024 ; 24 (16) : 1496-1520. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24020049

Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24020049
003      
CZ-PrNML
005      
20241024110913.0
007      
ta
008      
241015s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.2174/0113895575270904231129062137 $2 doi
035    __
$a (PubMed)38265369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Wani, Atif Khurshid $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India $1 https://orcid.org/0000000288201231
245    10
$a Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy / $c AK. Wani, R. Singh, N. Akhtar, A. Prakash, E. Nepovimova, P. Oleksak, Z. Chrienova, S. Alomar, C. Chopra, K. Kuca
520    9_
$a Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
650    _2
$a lidé $7 D006801
650    12
$a TOR serin-threoninkinasy $x antagonisté a inhibitory $x metabolismus $7 D058570
650    12
$a sarkom $x farmakoterapie $x metabolismus $x patologie $7 D012509
650    12
$a signální transdukce $x účinky léků $7 D015398
650    12
$a protoonkogenní proteiny c-akt $x metabolismus $x antagonisté a inhibitory $7 D051057
650    12
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    12
$a protinádorové látky $x farmakologie $x chemie $x terapeutické užití $7 D000970
650    _2
$a inhibitory fosfoinositid-3-kinasy $x farmakologie $x terapeutické užití $7 D000081082
650    _2
$a zvířata $7 D000818
650    _2
$a mTOR inhibitory $x farmakologie $x terapeutické užití $7 D000091203
650    _2
$a inhibitory proteinkinas $x farmakologie $x chemie $x terapeutické užití $7 D047428
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Singh, Reena $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
700    1_
$a Akhtar, Nahid $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
700    1_
$a Prakash, Ajit $u Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA $1 https://orcid.org/0000000176280457
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia $1 https://orcid.org/000000030281246X $7 xx0224758
700    1_
$a Oleksak, Patrik $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia
700    1_
$a Chrienova, Zofia $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia
700    1_
$a Alomar, Suliman $u King Saud University, Zoology Department, College of Science, Riyadh, 11451, Saudi Arabia
700    1_
$a Chopra, Chirag $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Králové, Czechia $1 https://orcid.org/0000000196641109 $7 xx0041831
773    0_
$w MED00008043 $t Mini reviews in medicinal chemistry $x 1875-5607 $g Roč. 24, č. 16 (2024), s. 1496-1520
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38265369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110907 $b ABA008
999    __
$a ok $b bmc $g 2202343 $s 1232022
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 16 $d 1496-1520 $e - $i 1875-5607 $m Mini reviews in medicinal chemistry $n Mini Rev Med Chem $x MED00008043
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...